{
    "clinical_study": {
        "@rank": "31766", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single arm study will evaluate the effect of RoActemra/Actemra in\n      combination with methotrexate on articular damage in the hand (synovitis/osteitis and\n      erosions) in patients with moderate to severe rheumatoid arthritis who have an inadequate\n      response to non-biological disease-modifying ante-rheumatic drugs (DMARDs). Patients will\n      receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for 24 weeks."
        }, 
        "brief_title": "A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Diagnosis of rheumatoid arthritis  according to ACR/EULAR classification (2010) of\n             >/= 6 months duration\n\n          -  Active moderate to severe rheumatoid arthritis (DAS >/= 3.2)\n\n          -  Swollen joint count (SJC) >/= 6, tender joint count >/= 8\n\n          -  Synovitis in the dominant hand\n\n          -  Inadequate response to stable dose of a non-biological DMARD for at least 3 months\n\n          -  Oral corticosteroids must have been on stable dose for at least 25 out of 28 days\n             before first dose of study drug\n\n          -  Patient on outpatient treatment\n\n        Exclusion Criteria:\n\n          -  Major surgery (including joint surgery) in the 8 weeks prior to screening, or planned\n             major surgery within 6 months of randomization\n\n          -  Rheumatic autoimmune disease other than rheumatoid arthritis\n\n          -  American College of Rheumatology (ACR) functional class IV\n\n          -  History of or current inflammatory joint disease other than rheumatoid arthritis\n\n          -  Previous inadequate response to a biologic DMARD; prior biologic therapy for no\n             longer than 1 month is allowed if discontinued for reasons of tolerability at least 6\n             months prior to study recruitment\n\n          -  Intra-articular or parenteral corticosteroids within 6 weeks prior to study start\n\n          -  Inadequate hematologic, renal or liver function\n\n          -  Positive for hepatitis B, hepatitis C or HIV infection\n\n          -  Pregnant or lactating women\n\n          -  History of severe allergic reactions or anaphylaxis to human, humanized or mural\n             monoclonal antibodies\n\n          -  Current infections or history of recurrent infections\n\n          -  History of or currently active primary or acquired immunodeficiency\n\n          -  Active tuberculosis requiring treatment in the previous 3 years\n\n          -  Body weight > 150 kg"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878318", 
            "org_study_id": "ML28204"
        }, 
        "intervention": [
            {
                "arm_group_label": "RoActemra/Actemra", 
                "description": "8 mg/kg intravenously every 4 weeks, 24 weeks", 
                "intervention_name": "tocilizumab [RoActemra/Actemra]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "RoActemra/Actemra", 
                "description": "stable dose", 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "number_of_arms": "1", 
        "official_title": "Open Label Study to Describe the Effect of Tocilizumab in Combination With MTX in the Evolution of Articular Damage (Synovitis/Osteitis and Erosions) Evaluated by MRI in the Hand of Patients With Moderate to Severe Rheumatoid Arthritis (RA) and Inadequate Response to Non-biological DMARDs", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Venezuela: Instituto Nacional de Higiene Rafael Rangel (INHRR)"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in extent and degree of synovitis in the hand assessed by MRI according to the OMERACT RAMRIS scale", 
            "safety_issue": "No", 
            "time_frame": "from baseline to Week 24"
        }, 
        "removed_countries": {
            "country": "Venezuela"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878318"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Radiological changes in the hand according to the modified Sharp scale", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Change in Ritchie articular index", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Proportion of patients with American College of Rheumatology (ACR 20/50/70) response at Weeks 12 and 24", 
                "safety_issue": "No", 
                "time_frame": "Weeks 12 and 24"
            }, 
            {
                "measure": "Change in pain: Visual analogue scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Change in disability: Stanford Health Assessment Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Change in FACIT-fatigue questionnaire", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Change in disease activity: Disease activity score 28 - erythrocyte sedimentation rate (DAS28-ESR)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 28"
            }, 
            {
                "measure": "Change in C-reactive protein", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Change in immunologic parameters: Rheumatic factor/anti-CCP", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}